Artivion (AORT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising ...

Medical device company Artivion (NYSE:AORT) missed Wall Street’s revenue expectations in Q4 CY2024 as sales rose 3.9% year on ...

Artivion (NYSE:AORT – Get Free Report) had its target price reduced by equities research analysts at Stifel Nicolaus from $33 ...

Shares of medical device company Artivion (NYSE:AORT) fell 11.2% in the morning session after the company reported weak fourth-quarter 2024 results, as both revenue and EPS missed Wall Street's ...

In a report released today, Frank Takkinen from Lake Street reiterated a Buy rating on Artivion (AORT – Research Report), with a price target ...

Artivion, Inc. (NYSE:AORT – Get Free Report)’s stock price gapped down before the market opened on Tuesday following a dissappointing earnings announcement. The stock had previously closed at $27.85, ...

Needham lowered the firm’s price target on Artivion (AORT) to $32 from $34 and keeps a Buy rating on the shares after its Q4 results. The ...

Q4 2024 Earnings Call Transcript February 24, 2025 Artivion, Inc. misses on earnings expectations. Reported EPS is $-0.39 EPS, expectations were $0.12. Operator: Greetings, and welcome to the Artivion ...

ARTIVION ($AORT) is expected to release its quarterly earnings data on Monday, February 24th after market close, per Finnhub. Analysts are expecting revenue of ...

ATLANTA - Artivion, Inc. (NYSE: AORT) saw its shares plunge 10% after-hours Monday after the cardiac and vascular surgery company reported fourth quarter revenue that fell short of analyst ...